Pompilio, G., Morabito, A., Cortinovis, D. L., & Integlia, D. (2022). Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. Global and Regional Health Technology Assessment, 9(1), 22–29. https://doi.org/10.33393/grhta.2022.2351